CD19 and diffuse large B-cell lymphoma: Deng et al. infused autologous axicabtagene ciloleucel (axi-cel) anti-CD19 CAR T-cell product in 24 patients with LBCL (2 PMBCL, 6 transformed follicular lymphoma (TFL), and 16 DLBCL), and then selected 137,326 residual cells for the whole transcriptome scRNA-seq test.